Allergan is a global, technology-driven multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential. In making this commitment, we work to develop an unparalleled level of insight into patients' wants and needs — and into the priorities and concerns of the medical specialists who treat them. To this end, we employ more than 50 percent of our work force in either research and development (R&D) or sales, ensuring our efforts are focused on innovation and our customers.
Allergan's flagship franchises in eye care, neurosciences, medical dermatology and urologics are structured under the company's pharmaceutical business portfolio, Allergan Pharmaceuticals. This portfolio offers specialty physicians and their patients a wide range of treatments to help preserve and protect sight, reduce physical disability and enhance quality of life.
With the acquisition of Inamed Corporation in 2006, Allergan added breast aesthetics and dermal fillers to its business portfolio to create a world-leading medical aesthetics franchise. All of these products are now represented within the Allergan Medical corporate division.
With specialty product lines focused on high-growth markets, Allergan represents a new multi-specialty health care model for the future, where diversification and focus live together to offer physicians and patients best-in-class treatments and a robust pipeline for continuous innovation. Bolstered by an integrated R&D organization and global infrastructure, characteristics of some of the industry's largest pharmaceutical companies, Allergan also maintains a lean and efficient operation with solid growth prospects, like many smaller and more specialized organizations in the health care field. Allergan is large enough to command sufficient resources to address significant patient needs yet small enough for nimble execution. As we look to the future, we will continue to follow our R&D technologies into additional specialty areas and build a leadership presence of relevance to the doctors and patients we serve.
Allergan, Inc. has developed a portfolio of the technologically advanced dermatology products to treat skin disease and improve the appearance of skin.
We have developed treatments to address common skin disorders including psoriasis and acne. Psoriasis, a chronic skin disorder than can take many different forms, afflicts as many as 7.5 million Americans, according to the National Psoriasis Foundation1. With acne, an estimated 80 percent of people between the ages of 11 and 30 have outbreaks at some point,2 and acne can persist well into adulthood.3 Our dermatology portfolio includes, TAZORAC® (tazarotene), the first topical receptor selective retinoid approved for psoriasis and acne, and ACZONE® (dapsone) Gel 5%, approved for the topical treatment of acne vulgaris.
Another common chronic condition affecting 7.8 million Americans is hyperhidrosis, which is the term for excessive sweating.4 Patients with hyperhidrosis produce an amount of sweat that far exceeds that needed to regulate body temperature. BOTOX® (onabotulinumtoxinA) is approved for severe primary axillary hyperhidrosis (excessive underarm sweating) that is not adequately managed by topical agents. Please see important limitations below.